| 1 |
Management of acute kidney injury in symptomatic multiple myeloma |
|
|
| Frank Bridoux, Nelson Leung, Mohamed Belmouaz, Virginie Royal, Pierre Ronco, Samih H. Nasr, Jean Paul Fermand |
|
| Kidney International. 2021; 99(3): 570 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 2 |
Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group |
|
|
| Evangelos Terpos, Elena Zamagni, Suzanne Lentzsch, Matthew T Drake, Ramón García-Sanz, Niels Abildgaard, Ioannis Ntanasis-Stathopoulos, Fredrik Schjesvold, Javier de la Rubia, Charalampia Kyriakou, Jens Hillengass, Sonja Zweegman, Michele Cavo, Philippe Moreau, Jesus San-Miguel, Meletios A Dimopoulos, Nikhil Munshi, Brian G M Durie, Noopur Raje |
|
| The Lancet Oncology. 2021; 22(3): e119 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 3 |
Kidney injury and disease in patients with haematological malignancies |
|
|
| Frank Bridoux, Paul Cockwell, Ilya Glezerman, Victoria Gutgarts, Jonathan J. Hogan, Kenar D. Jhaveri, Florent Joly, Samih H. Nasr, Deirdre Sawinski, Nelson Leung |
|
| Nature Reviews Nephrology. 2021; 17(6): 386 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 4 |
Controversies in the use of new bone-modifying therapies in multiple myeloma |
|
|
| Evangelos Terpos, Ioannis Ntanasis-Stathopoulos |
|
| British Journal of Haematology. 2021; 193(6): 1034 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 5 |
Myeloma-related Kidney Disease |
|
|
| Nelson Leung,Samih H. Nasr |
|
| Advances in Chronic Kidney Disease. 2014; 21(1): 36 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 6 |
Zalecenia Polskiej Grupy Szpiczakowej dotyczace rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2013 |
|
|
| Anna Dmoszynska,Adam Walter-Croneck,Lidia Usnarska-Zubkiewicz,Beata Stella-Holowiecka,Jan Walewski,Grzegorz Charlinski,Wieslaw Wiktor Jedrzejczak,Elzbieta Wiater,Ewa Lech-Maranda,Joanna Manko,Dominik Dytfeld,Mieczyslaw Komarnicki,Krzysztof Jamroziak,Tadeusz Robak,Artur Jurczyszyn,Aleksander Skotnicki,Krzysztof Giannopoulos |
|
| Acta Haematologica Polonica. 2013; 44(1): 3 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 7 |
Osteoporosis treatment: why ibandronic acid? |
|
|
| Maurizio Rossini,Giovanni Orsolini,Silvano Adami,Vidya Kunnathully,Davide Gatti |
|
| Expert Opinion on Pharmacotherapy. 2013; 14(10): 1371 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 8 |
Dosing related effects of zoledronic acid on bone markers and creatinine clearance in patients with multiple myeloma and metastatic breast cancer |
|
|
| Kent Søe,Jean-Marie Delaissé,Erik H. Jakobsen,Charlotte T. Hansen,Torben Plesner |
|
| Acta Oncologica. 2013; : 1 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 9 |
Osteoporosis treatment: Why ibandronic acid? |
|
|
| Rossini, M. and Orsolini, G. and Adami, S. and Kunnathully, V. and Gatti, D. |
|
| Expert Opinion on Pharmacotherapy. 2013; 14(10): 1371-1381 |
|
| [Pubmed] [Google Scholar] |
|
| 10 |
Guidelines of Polish Myeloma Group concerning diagnosis and therapy of multiple myeloma and other plasmacytic dyscrasias for 2013 [Zalecenia PolskiejGrupy Szpiczakowejdotycza̧ce rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2013] |
|
|
| Dmoszyńska, A. and Walter-Croneck, A. and Usnarska-Zubkiewicz, L. and Stella-Hołowiecka, B. and Walewski, J. and Charliński, G. and Jȩdrzejczak, W.W. and Wiater, E. and Lech-Marańda, E. and Mańko, J. and Dytfeld, D. and Komarnicki, M. and Jamroziak, K. and Robak, T. and Jurczyszyn, A. and Skotnicki, A. and Giannopoulos, K. |
|
| Acta Haematologica Polonica. 2013; 44(1): 3-47 |
|
| [Pubmed] [Google Scholar] |
|
| 11 |
Renal function in IV bisphosphonate therapy in common practice [Renálnà funkce při i.v. terapii bisfosfonáty v běžné praxi osteocentra] |
|
|
| BubenÃÄek, P. and Kasalický, P. and Rosa, J. |
|
| Osteologicky Bulletin. 2012; 17(3): 84-89 |
|
| [Pubmed] [Google Scholar] |
|
| 12 |
Renal complications from bisphosphonate treatment |
|
|
| Hirschberg, R. |
|
| Current Opinion in Supportive and Palliative Care. 2012; 6(3): 342-347 |
|
| [Pubmed] [Google Scholar] |
|
| 13 |
Current Approach to Diagnosis and Management of Acute Renal Failure in Myeloma Patients |
|
|
| Leung, N. and Behrens, J. |
|
| Advances in Chronic Kidney Disease. 2012; 19(5): 297-302 |
|
| [Pubmed] [Google Scholar] |
|
| 14 |
Effects of zoledronic acid and ibandronic acid on renal functions and calcium, phosphorus and alkaline phosphatase levels in breast cancer patients with bone metastases: A retrospective analysis |
|
|
| Fidan, E., Yildiz, B., Kavgaci, H., Ozdemir, F., Aydin, F. |
|
| Wspolczesna Onkologia. 2012; 16(2): 176-178 |
|
| [Pubmed] [Google Scholar] |
|
| 15 |
Denosumab for treatment of breast cancer bone metastases and beyond |
|
|
| Nangia, J.R., Ma, J.D., Nguyen, C.M., Mendes, M.A.S., Trivedi, M.V. |
|
| Expert Opinion on Biological Therapy. 2012; 12(4): 491-501 |
|
| [Pubmed] [Google Scholar] |
|
| 16 |
Lower dose dexamethasone/thalidomide and zoledronic acid every 3 weeks in previously untreated multiple myeloma |
|
|
| Teoh, G., Chen, Y., Kim, K., Srivastava, A., Pai, V.R., Yoon, S.-S., Suh, C., Kim, Y.-K. |
|
| Clinical Lymphoma, Myeloma and Leukemia. 2012; 12(2): 118-126 |
|
| [Pubmed] [Google Scholar] |
|
| 17 |
Perspectives in the elderly patient: Benefits and limits of bisphosphonates and denosumab |
|
|
| Santini, D., Fratto, M.E., Aapro, M. |
|
| Recent Results in Cancer Research. 2012; 192: 171-182 |
|
| [Pubmed] [Google Scholar] |
|
| 18 |
Therapeutic approaches to myeloma bone disease: An evolving story |
|
|
| Longo, V., Brunetti, O., DæOronzo, S., Dammacco, F., Silvestris, F. |
|
| Cancer Treatment Reviews. 2012; 38(6): 787-797 |
|
| [Pubmed] [Google Scholar] |
|
| 19 |
Denosumab for treatment of breast cancer bone metastases and beyond |
|
|
| Julie R Nangia,Joseph D Ma,Christine M Nguyen,Margaret AS Mendes,Meghana V Trivedi |
|
| Expert Opinion on Biological Therapy. 2012; 12(4): 491 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 20 |
Lower Dose Dexamethasone/Thalidomide and Zoledronic Acid Every 3 Weeks in Previously Untreated Multiple Myeloma |
|
|
| Gerrard Teoh,Yuming Chen,Kihyun Kim,Alok Srivastava,Vasant R. Pai,Sung-Soo Yoon,Cheolwon Suh,Yeo-Kyeoung Kim |
|
| Clinical Lymphoma Myeloma and Leukemia. 2012; 12(2): 118 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 21 |
Therapeutic approaches to myeloma bone disease: An evolving story |
|
|
| Vito Longo,Oronzo Brunetti,Stella D’Oronzo,Franco Dammacco,Franco Silvestris |
|
| Cancer Treatment Reviews. 2012; 38(6): 787 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 22 |
Renal complications from bisphosphonate treatment |
|
|
| Raimund Hirschberg |
|
| Current Opinion in Supportive and Palliative Care. 2012; 6(3): 342 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 23 |
Current Approach to Diagnosis and Management of Acute Renal Failure in Myeloma Patients |
|
|
| Nelson Leung,Judith Behrens |
|
| Advances in Chronic Kidney Disease. 2012; 19(5): 297 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 24 |
Assessment of the efficacy of pulse Ibandronate therapy in non-steroidal anti-inflammatory drug refractory ankylosing spondylitis: An open prospective study |
|
|
| Rathindra Nath Sarkar,Kuntal Bhattacharyya,Sibaji Phaujdar,Dibyendu De |
|
| Indian Journal of Rheumatology. 2011; 6(2): 55 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 25 |
The Role of Bisphosphonates in Multiple Myeloma: Mechanisms, Side Effects, and the Future |
|
|
| Samantha Pozzi, Noopur Raje |
|
| The Oncologist. 2011; 16(5): 651 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 26 |
Sustained bone pain relief in breast cancer patients with metastatic bone disease treated with ibandronate: Final results of a large-scale noninterventional study |
|
|
| Diel, I.J., Schmidt, M., Maasberg, M., Bergner, R. |
|
| European journal of Clinical and Medical Oncology. 2011; 3(4): 17-23 |
|
| [Pubmed] [Google Scholar] |
|
| 27 |
The role of bisphosphonates in multiple myeloma: Mechanisms, side effects, and the future |
|
|
| Pozzi, S., Raje, N. |
|
| Oncologist. 2011; 16(5): 651-662 |
|
| [Pubmed] [Google Scholar] |
|
| 28 |
Multiple myeloma, severe hypercalcemia, acute renal failure and multiple organ failure due to calcinosis | [Mieloma múltiple, hipercalcemia severa, insuficiencia renal aguda y fallo multiorgánico por calcinosis] |
|
|
| Mateu, J.G.M., González, G.P.L., Vila, M.A.M., Rivera, M.U., Marqués, G.G., Tugores, A.C. |
|
| Nefrologia. 2011; 31(2): 233-234 |
|
| [Pubmed] [Google Scholar] |
|
| 29 |
Assessment of the efficacy of pulse Ibandronate therapy in non-steroidal anti-inflammatory drug refractory ankylosing spondylitis: An open prospective study |
|
|
| Sarkar, R.N., Bhattacharyya, K., Phaujdar, S., De, D. |
|
| Indian Journal of Rheumatology. 2011; 6(2): 55-60 |
|
| [Pubmed] [Google Scholar] |
|
| 30 |
Optimising bisphosphonate treatment outcomes in postmenopausal osteoporosis: Review and Italian experience |
|
|
| Rossini, M. and Di Munno, O. and Gatti, D. and Giannini, S. and Minisola, S. and Varenna, M. and Adami, S. |
|
| Clinical and Experimental Rheumatology. 2011; 29(4): 728-735 |
|
| [Pubmed] [Google Scholar] |
|
| 31 |
Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models |
|
|
| Rousseau, J., Escriou, V., Lamoureux, F., Brion, R., Chesneau, J., Battaglia, S., Amiaud, J., (...), Trichet, V. |
|
| Journal of Bone and Mineral Research. 2011; 26(10): 2452-2462 |
|
| [Pubmed] [Google Scholar] |
|
| 32 |
Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models |
|
|
| Julie Rousseau,Virginie Escriou,François Lamoureux,Régis Brion,Julie Chesneau,Séverine Battaglia,Jérome Amiaud,Daniel Scherman,Dominique Heymann,Françoise Rédini,Valérie Trichet |
|
| Journal of Bone and Mineral Research. 2011; 26(10): 2452 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
